Organisation › Details

VarmX B.V.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center (LUMC), founded in 2016 by professor Pieter Reitsma, a world leading expert in hemostasis and thrombosis. CEO is Paul Bilars, former managing director of one of LUMC’s divisions. In this capacity, he was also responsible for valorization of IP and strategic sourcing. Product development is based on R&D performed by one of the world’s leading groups in hemostasis and thrombosis at the Leiden University Medical Center (LUMC), led by professor Reitsma. The company’s leading product in development, PseudoXa, is a new therapeutic protein, based on the innovative research into the properties of a snake venom, to prevent or stop severe bleeding in patients taking factor Xa inhibitors, such as the commonly used apixaban. *


Period Start 2017-06-27 splitoff before
  Predecessor Leiden University Medical Center (LUMC)
Products Industry therapeutic protein
  Industry 2 PseudoXa
Persons Person Bilars, Paul (VarmX BV 201706 CEO)
  Person 2 Reitsma, Pieter (VarmX BV 201706 CSO)
Region Region Leiden
  Country Netherlands
  Street 38 B Middelweg
  City 2312 KJ Leiden
  Tel +31-71-5156127
    Address record changed: 2018-07-10
Basic data Employees n. a.
    * Document for �About Section�: VarmX B.V.. (7/2/18). "Press Release: VarmX Raises € 12.5 Million to Develop Modified Blood Coagulation Factor X for Treating Severe Bleeding in Patients Using Anti-Coagulants". Leiden.
Record changed: 2019-05-30


[iito] Business Intelligence – The Elephants Are Coming 560x91px

More documents for VarmX B.V.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] – Putting Information into Context 600x60px

» top